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Summary Gemcitabine (GEMZARO) is a novel nucleoside analogue with activity in a range of preclinical models both in vitro and in vivo. It is
highly schedule dependent, with weekly x3 every 4 weeks being the recommended schedule for phase 11/111 studies. Early phase 11 trials
identified activity against non-small-cell lung cancer and pancreatic cancers, tumour types for which gemcitabine has a licence for treatment
in many countries. However, the preclinical models indicated that gemcitabine may be active against many other human solid tumours. In
phase 11 studies, activity has been identified against breast cancer, both as a single agent and in combination. In bladder cancer, impressive
single-agent activity of gemcitabine has also been seen, as well as in combination with cisplatin, initially in MVAC and platinum failures but
more recently as first-line therapy both as a single agent and combined with cisplatin. Anti-tumour activity has also been seen in patients with
ovarian cancer, head and neck cancer, small-cell lung cancer and cervical cancer, with minimal activity in renal carcinoma, prostate and colon
cancer. In view of the excellent side-effect profile and the potential for gemcitabine to inhibit DNA repair after exposure to DNA-damaging
agents, further developments of gemcitabine will include its use in combination chemotherapy and combined modality schedules.
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Gemcitabine (2'2'-difluorodeoxycytidine, dFdC) is a novel nucleo-
side analogue ofdeoxycytidine recently introduced forthe treatment
ofpancreatic cancer and non-small-cell lung cancer (NSCLC).
Gemcitabine is inactive in the parental form but is progressively
phosphorylated intracellularly, in an identical manner to cytosine
arabinoside, to its active diphosphate and triphosphate metabolites
via kinases, including deoxycytidine kinase. The diphosphate
inhibits ribonucleotide reductase (Heinemann et al, 1990), and the
triphosphate is incorporated into DNA as a fraudulent base in
competition with dCTP (Huang et al, 1991). Incorporation of
dFdCTP into DNA results in DNA chain termination, as the fraud-
ulent base is relatively resistant to excision repair (Huang et al,
1991). Deactivation of gemcitabine occurs via deamination, with
most of the drug being eliminated in this form via the renal route
(Plunkett et al, 1989; Abbruzzese et al, 1991).
In early clinical trials, the efficacy and tolerability of gem-
citabine was shown to be highly schedule dependent, the
maximum-tolerated dose (MTD) ranging from 12 mg m-2 on a
daily x5 schedule to over 4.5 g m-2 using a 2-weekly regimen.
Dose-limiting toxicities varied with different schedules, with
hypotension and fatigue noted on the daily x5 schedule. Activity
was identified using many schedules and the weekly x3 every 4
weeks schedule was found to be extremely well tolerated by the
majority ofpatients. This schedule was therefore chosen for phase
II development (Kaye, 1994).
Gemcitabine has been shown to have significant activity in
NSCLC. Single-agent gemcitabine at a dose of 800-1250 mg m-2
exhibited reproducible response rates of around 20% in a number
of studies (Abratt et al, 1994; Anderson et al, 1994; Gatzemeier et
al, 1996). Recently, a combination of gemcitabine with cisplatin
has been evaluated in NSCLC, for which response rates in the
region of50% have been seen, with median survival ofover 1 year
(Abratt et al, 1997; Crino et al, 1997). Many randomized trials are
currently underway that compare the gemcitabine-cisplatin
combination with standard combination chemotherapy schedules,
such as cisplatin-etoposide and MIC (mitomycin, ifosfamide and
cisplatin), and one study has compared single-agent gemcitabine
with best supportive care.
In early studies in pancreatic cancer, activity was evident but the
response rates achieved were modest (Casper et al, 1994;
Carmichael et al, 1996a). It was noted in these studies, however,
that a number of patients had stable disease and remained
symptom free for prolonged periods. A randomized study was
therefore performed comparing gemcitabine with weekly 5-fluo-
rouracil (5-FU) (Burris, 1997). The main end point of this study
was symptom benefit, and standard response criteria were
secondary end points. The response rate was low, 5.4% for gem-
citabine vs 0% for 5-FU, but clinical benefit responses (Von Hoff,
1996) were observed in 24% ofcases compared with 5% for 5-FU.
Of interest, median survival and 1-year survival rates were also
superior for gemcitabine (Burris, 1997). Gemcitabine is now
marketed in many countries for the therapy ofpancreatic cancer.
In view of its excellent side-effect profile, gemcitabine is now
under evaluation in a number ofother tumours as a single agent as
well as in combination schedules.
BREAST CANCER
There have been two phase II studies completed using gemcitabine
in breast cancer. These studies were performed in patients with
locally advanced or metastatic disease, the majority of whom had
previously received chemotherapy. In both studies, gemcitabine Correspondence to: J Carmichael
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Table 1 Activity of gemcitabine in breast cancer
Carmichael et al (1995) Blackstein et al (1996) Spielmann et al (1996) Garcia-Conde et al (1997)
Patients 1st/2nd Line 1st Line Anthracycline resistant 1st Line
Gemcitabine dose 800 1200 1200 800 or 1000
(mg m-2 days 1, 8 and 15) (Doxorubicin dose 25)
Patients entered/evaluable 44/40 36/26 36/27 42/42
Response rate (%) 25 46 29 60
Table 2 Activity of gemcitabine in ovarian cancer
Lund et al (1994) Underhill et al (1996) Neijt et al (1996) Shapiro et al (1996)
Gemcitabine dose 800 1250 1250 1000
(mg m-2 days 1, 8 and 15)
Patients entered/evaluable 50/42 35/33 40/36 38/31
Response rate (%) 19 24 22 13
Table 3 Activity of gemcitabine in bladder cancer
Pollera et al De Lena et al Stadler et al Moore et al von der Maase Stadler et al
(1994) (1996) (1996) (1996) et al (1997) (1997)
Gemcitabine dose 875-1370 1250 1200 1200 1000 + 35 Cisplatin 1000 + 100 Cisplatin
(mg m-2 days 1, 8 and 15) Days 1, 8 and 15 Day 1
Patients entered/evaluable 15/15 34/25 40/38 40/21 44/38 31/17
Response rate (%) 27 28 29 38 40 65
was administered as a 30-min infusion at a dose of 800 mg m-2 on
days 1, 8 and 15 of a 28-day cycle. In a European study
(Carmichael et al, 1995), a 25% response rate was identified in 40
evaluable patients in a two-centre study. In a USA study, no
responses were seen in 18 evaluable patients (Carmichael and
Walling, 1996). Variability in these results may be explained by a
number of parameters. Dose intensity was higher in the European
study, with a far greater number of dose reductions in the USA
study. Patients had received more prior chemotherapy in the USA
study, and the median number of gemcitabine courses adminis-
tered was lower. Details of these patients are shown in Table 1,
along with characteristics of patients on other breast cancer trials
using gemcitabine. Responses were identified in both chemonaive
and previously treated patients, with responses observed at all
metastatic sites.
In view of the variability in response rates, further studies were
performed in breast cancer patients. A study was performed in
patients previously treated with anthracyclines (Spielmann et al,
1996). All patients had responded to anthracycline treatment for
metastatic breast cancer for at least 6 months. These patients
received gemcitabine 1200 mg m-2 weekly x3 every 4 weeks. In
addition, 15 patients had received adjuvant chemotherapy. Of 36
patients entered, 27 were evaluable, in whom two complete respon-
ders and six partial responders were observed, giving a response
rate of29%. Asthenia was dose limiting in this study, with minimal
haematological toxicity. One single-agent study has been
performed in chemonaive patients (Blackstein et al, 1996). Patients
received gemcitabine (1200 mg m-2) weekly x3 every 4 weeks. Of
36 patients entered, 21 had received prior adjuvant chemotherapy
that was completed 1 yearpreviously. The majority ofpatients were
premenopausal and oestrogen receptor (ER) positive. A 46%
response rate was reported in 26 evaluable patients, with two
complete responders (CR) and ten partial responders in a prelimi-
nary communication. The chemotherapy was well tolerated, with
only one grade 4 neutropenia and no significant thrombocytopenia.
In view ofthe single-agent activity in breast cancer, a number of
groups are currently evaluating combination chemotherapy regi-
mens. A combination of gemcitabine and doxorubicin has been
shown to be well tolerated and active, with responses observed in
21 of42 evaluable patients (overall response rate 60%), in patients
who were chemonaive in the metastatic disease setting, but all of
whom had received adjuvant chemotherapy (Garcia-Conde et al,
1997). Severe myelosuppression was seen in two out of six
patients treated with gemcitabine at a dose of 1000 mg m-2 weekly
x3 every 4 weeks with doxorubicin 25 mg m-2 weekly on the same
schedule. The recommended dose for phase III studies is gem-
citabine 800 mg m-2 weekly x3 every 4 weeks with doxorubicin
25 mg m-2 on the same days. Other toxicities were minimal.
Another group is evaluating gemcitabine in combination with
epirubicin in a phase I study (Luftner et al, 1996). The recom-
mended doses for phase II studies are gemcitabine 1000 mg m-2
weekly x3 every 4 weeks with epirubicin 15 mg m-2 weekly. Other
phase I studies with paclitaxel, docetaxel and vinorelbine are
currently underway.
OVARIAN CANCER
Activity of gemcitabine in the treatment of ovarian cancer was
first reported by Lund et al (1994). Of 50 patients with recurrent
ovarian cancer treated with gemcitabine at a dose of 800 mg m-2
weekly x3 every 4 weeks, 42 were evaluable, in whom a 19%
response rate was reported. Many of these patients were consid-
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Table 4 Activity of gemcitabine in other cancers
No. of patients Response Reference
evaluable rate (%)
Renal 18 6 Mertens et al (1993)
Renal 37 8 De Mulder et al (1996)
Cervix 45 11 Goedhals and Bezwoda (1996)
Head and neck 33 13 Catimel et al (1994)
SCLC 26 27 Cormier et al (1994)
out of 54 (13%) patients (Table 4), with responses seen in both
previously treated and chemonaive patients (Catimel et al, 1994).
SMALL-CELL LUNG CANCER
Gemcitabine was evaluated in extensive stage small-cell lung
cancer, in previously untreated patients (Cormier et al, 1994). An
objective response rate of 27% was reported in 26 evaluable
patients receiving gemcitabine 1000-1250 mg m- in the standard
schedule (Table 4).
CERVICAL CANCER
ered to have a poor prognosis, with platinum refractory and/or
bulky disease. The study was subsequently extended to chemo-
naive patients who were treated with gemcitabine 1250 mg m-2
weekly x3 every 4 weeks (Underhill et al, 1996). Of the 35
patients enrolled, 33 were evaluable. A response rate of 24% was
seen in primarily stage IV patients. A further study used gem-
citabine 1250 mg m-2 in platinum-resistant patients who had
relapsed 1-12 months after platinum therapy. A 22% response rate
was seen in 36 evaluable patients who received gemcitabine
1250 mg m-2 (Neijt et al, 1996). Shapiro and colleagues (1996)
reported a 13% response rate in 38 patients (31 of whom were
assessable) previously treated with cisplatin. Twenty-seven of
these had previously received paclitaxel, indicating activity of
gemcitabine in heavily pretreated patients (Shapiro et al, 1996).
These data are summarized in Table 2.
BLADDER CANCER
A number of studies have indicated activity of gemcitabine in
bladder cancerpatients. Pollera et al (1994) reported a 27% response
rate, including one complete response, in 15 patients with bladder
cancer, 14 of whom had previously received methotroxate,
vincristine, doxorubicin and cisplatin (MVAC) chemotherapy.
Patients received 875-1370 mg m- doses of gemcitabine in this
phase I study. Significant myelotoxicity was seen at the highest
dose, resulting in treatment delays in approximately 50% of the
patients treated at this dose. De Lena et al (1996) reported a 28%
response rate in 25 evaluable cisplatin-pretreated patients. In two
subsequent studies, untreated patients received gemcitabine 1200
mg m-2 weekly x3 every 4 weeks with response rates of 29%
(Stadler et al, 1996) and 38% (Moore et al, 1996) in 38 and 21 evalu-
able patients respectively. These data are illustrated in Table 3.
Two studies have investigated the effect ofgemcitabine in combi-
nation with cisplatin. In the first, carried out in European centres,
gemcitabine (1000 mg m-2) was administered on days 1, 8 and 15 of
a 28-day cycle. Cisplatin (35 mg m-2) was given on the same days
(von der Maase et al, 1997). In 38 evaluable patients, four complete
and 11 partial responses were seen, for an overall response rate of
40%. Stadler and colleagues (1997) used the same gemcitabine
schedule, but only gave cisplatin (100 img m-2) on day I ofthe cycle.
Using this schedule, eight complete and three partial responses were
seen in 17 evaluable patients, giving an overall response rate of
65%. Final results are not yet available from this study.
HEAD AND NECK CANCER
Gemcitabine has been evaluated in head and neck cancer, as
preclinical activity in this tumour type has been described previ-
ously (Braakhuis et al, 1991). Catimel reported responses in seven
One phase II study has been reported in cervical cancer (Goedhals
and Bezwoda, 1996). Forty-nine patients were entered into the
study, 45 of whom were evaluable. Partial responses were seen in
five patients (11 %), and symptomatic responses were seen in addi-
tional patients. However, the compliance on this study was poor,
suggesting that the activity ofgemcitabine in this tumour type may
be significantly higher (Table 4).
RENAL CANCER
Two phase II studies have been performed in patients with renal
cancer (Table 4). Only modest activity was seen, with the first
study reporting one response in 18 patients (Mertens et al, 1993)
and the other an 8% response rate in 37 evaluable patients (De
Mulder et al, 1996). The toxicity ofgemcitabine was minimal and
the responses were durable. However, gemcitabine appears to have
a limited role in renal cancer.
CONCLUSION
Gemcitabine has significant activity against a variety of malignan-
cies and is currently licensed in many countries for the treatment of
NSCLC and pancreatic cancer. Early studies showed that gemc-
itabine was extremely well tolerated. The most common dose-
limiting toxicity is myelosuppression, although this is generally
mild when gemcitabine is used as a single agent. Haematological
sequelae of myelosuppression are extremely rare, and dose inten-
sity in most gemcitabine single-agent studies approaches 100%.
Gemcitabine has very few symptomatic toxicities. Nausea and
vomiting are extremely mild and are rare compared with other cyto-
toxic drugs. Likewise, alopecia is extremely unusual.
The relative lack of side-effects in phase I and II studies and the
relative lack of myelosuppression makes gemcitabine an ideal
drug to consider for combination chemotherapy protocols.
Preclinical studies show that gemcitabine is synergistic with many
DNA-damaging agents, including platinum drugs and irradiation.
Early phase II clinical studies, primarily in NSCLC, have shown
that gemcitabine-cisplatin combinations are extremely active and
are also well tolerated by the majority of patients (Abratt et al,
1997; Crin6 et al, 1997). Thus patients with NSCLC may benefit
from either palliative single-agent gemcitabine or a more intensive
combination chemotherapy regimen. Likewise, we have shown
that the combination of gemcitabine and carboplatin is extremely
well tolerated by the majority of patients and is also extremely
active in NSCLC (Carmichael et al, 1996b).
Anti-cancer activity has also been seen in breast cancer and
bladder cancer. In breast cancer, there may be a role forgemcitabine
as a single agent in elderly patients or patients with a poor prognosis
who are unsuitable for more aggressive therapy; in addition, hair
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loss could be avoided in these patients. The data on combination
chemotherapy regimens are preliminary, although the gem-
citabine-doxorubicin data appear extremely encouraging at this
time. Identification of appropriate schedules for combinations of
gemcitabine and taxanes, as well as gemcitabine and vinorelbine,
will offer exciting options forthe treatment ofbreast cancerpatients.
The data from trials in bladder cancer are particularly impressive.
Activity has been identified in both previously treated and chemo-
naive patients. Single-agent response rates of approximately 30%
have been seen in different populations and, together with the
taxanes, gemcitabine offers a realistic hope ofimproved outcome in
these patients. The favourable toxicity profile of gemcitabine is
particularly relevant in this disease, as many patients may not be
able to tolerate more aggressive regimens. Results from combina-
tion chemotherapy regimens with taxanes and platinum drugs are
also awaited with interest; such regimens may prove to have a better
overall acceptability than current 'standard' schedules.
Anti-cancer activity has also been described in SCLC and
ovarian cancer, although the precise role for gemcitabine in these
tumour types remains unclear. Further single-agent and combina-
tion chemotherapy regimens are indicated in these tumours.
Modest activity has been reported in other tumour types, such as
head and neck cancer and cervical cancer. However, as these are
tumours in which combinations with cisplatin and/or radiation are
frequently used, further evaluation is appropriate, particularly
combination chemotherapy and combined modality therapies.
Gemcitabine is a new nucleoside analogue with impressive
activity in early clinical trials. It is extremely well tolerated by the
majority ofpatients and is ideal for incorporation into combination
schedules. Gemcitabine is widely used in NSCLC and pancreatic
cancer, but many questions remain unanswered, including the
activity of gemcitabine in many solid tumours.
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